For US Healthcare Professionals

Resources

Initiation, Access & Approval

Resources to help get your patients started on VYJUVEK

KRYSTAL CONNECT ENROLLMENT FORM

Filling out this form is the first step toward VYJUVEK treatment. It is the prescription form for VYJUVEK and enables patient enrollment into Krystal Connect.

Download Now
CODING AND BILLING GUIDE

This guide provides general information on coding, coverage, billing, and reimbursement for VYJUVEK.

Download Now
ACQUIRING VYJUVEK GUIDE

This overview details the ordering and purchasing options for VYJUVEK.

Download Now
SAMPLE FORMULARY EXCEPTION LETTER

A template you can use to request VYJUVEK prior to it being on formulary.

Download Now
SAMPLE LETTER OF MEDICAL NECESSITY

A template you can use as a reference when writing a Letter of Medical Necessity to your patient's insurance company.

Download Now
SAMPLE LETTER OF APPEAL

A template you can use as a reference when writing a Letter of Appeal to your patient's insurance company requesting that it authorize coverage for VYJUVEK.

Download Now
PRIOR AUTHORIZATION CHECKLIST

This checklist will help navigate the process of submitting a Prior Authorization for VYJUVEK, should one be required.

Download Now
KRYSTAL CONNECT OVERVIEW

A summary of the personalized patient support provided by the Krystal Connect Program and an overview of the steps to getting a patient started on VYJUVEK.

Download Now

Preparation & administration

Information about the preparation and administration of VYJUVEK

PREPARATION GUIDE

A brochure with step-by-step guidance on how to prepare VYJUVEK for administration.

Download Now
ADMINISTRATION GUIDE

This brochure provides instructions on how to properly administer VYJUVEK to patients.

Download Now
VYJUVEK PREPARATION VIDEO

See the steps necessary to mix and prepare VYJUVEK.

VYJUVEK ADMINISTRATION VIDEO

Watch a step-by-step demonstration of how to administer VYJUVEK to your patient's DEB wounds.


Patient resources

Helpful information to share with your patients or their caregivers about VYJUVEK and DEB

VYJUVEK PATIENT BROCHURE

Information about VYJUVEK for DEB patients and their caregivers.

Download Now
KRYSTAL CONNECT BROCHURE

Introduction to support services available to patients and their caregivers through Krystal Connect.

Download Now
FIND A DOCTOR TOOL

This tool can be shared with patients who are trying to find a doctor in their area who treats DEB.

Find a Doctor

VYJUVEK EXPERIENCES

Hear about real-world experience with VYJUVEK

KOL VIDEO

Video Description FPO

PATIENT TESTIMONIAL
PATIENT TESTIMONIAL

Video Description FPO

For questions about resources or getting patients started on VYJUVEK, call Krystal Connect at
1-844-5-KRYSTAL or connect with us.

Connect With Us
INDICATION AND USAGE

VYJUVEK is a topical gel indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII (COL7A1) gene.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds for approximately 24 hours following treatment. Wear protective gloves when assisting subjects with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.

Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.

Dispose all materials (e.g., vial, syringe, needle, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard bag or container.

ADVERSE REACTIONS

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.


IMPORTANT SAFETY INFORMATION
INDICATION AND USAGE

VYJUVEK is a topical gel indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII (COL7A1) gene.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds for approximately 24 hours following treatment. Wear protective gloves when assisting subjects with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.

Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.

Dispose all materials (e.g., vial, syringe, needle, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard bag or container.

ADVERSE REACTIONS

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.